About this episode
Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs’ demand means for the biopharma industry’s five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks. Why GLP-1 Drugs Are in Demand Competition Between Novo Nordisk and Eli Lilly How Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance Coverage Are Weight Loss Drugs a Threat to Snack Food Stocks? Big Pharma’s Looming Patent Cliff How Medicare Negotiations Impact the Pharmaceutical Industry What is a Biologic Drug? Upcoming Innovations in the Pharmaceutical Industry Which BioPharma Drugs Do We Expect to Contract? Big Pharma’s Five-Year Outlook Biopharmaceutical Stock Picks Read about topics from this episode. 2024 Biopharmaceutical Industry Landscape Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? Investment Opportunities in the Biopharma Industry Obesity Drug Market: The Next Wave of GLP-1 Competition What to watch from Morningstar. Is the Fed’s Plan to Avoid a Recession Working? Don't Overlook These Crucial Parts of Your Retirement Plan Boating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks 5 Ways to Improve America’s Retirement Savings Read what our team is writing: Karen Andersen Ivanna Hampton Follow us on social media. Facebook: https://www.facebook.com/MorningstarInc/ X: https://x.com/MorningstarInc Instagram: https://www.instagram.com/morningstar ... LinkedIn: https://www.linkedin.com/company/5161/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.